BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with IC50 of 8 nM

CHMFL-EGFR-202 can form a covalent bond with Cys797 in a distinct "DFG-in-C-Helix-out" inactive EGFR conformation.